Targeting the SPHK1/S1P axis represents a promising therapeutic strategy.
Abstract Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by the loss of self-tolerance and multi-organ inflammation. Recent research has identified sphingosine kinase 1 (SPHK1) and its product, sphingosine-1-phosphate (S1P), as critical regulators in immune cell trafficking and inflammation. This paper reviews the current understanding of the SPHK1/S1P axis in SLE pathogenesis, highlighting its role in T-cell dysfunction, B-cell activation, and lupus nephritis, and discusses its potential as a therapeutic target. lupus spank
Lupus symptoms vary widely among individuals and can include: Lupus symptoms vary widely among individuals and can
Systemic Lupus Erythematosus (SLE) is a chronic, heterogeneous autoimmune disease that can affect the skin, joints, kidneys, brain, and other organs. The etiology of SLE involves a complex interplay of genetic susceptibility, environmental triggers, and hormonal factors, all leading to a breakdown in immune tolerance. Despite advances in treatment, current therapies often rely on broad immunosuppression, which carries significant side effects. Consequently, there is a pressing need for targeted therapies. The sphingosine kinase 1 (SPHK1) pathway has emerged as a significant area of interest due to its role in regulating lymphocyte egress and inflammatory signaling. and hormonal factors